Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease
Information source: Chinese PLA General Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Kidney Disease
Intervention: Valsartan (Drug); Perindopril (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Chinese PLA General Hospital Official(s) and/or principal investigator(s):
RiBao Wei, Master, Study Chair, Affiliation: Department of Nephrology, Chinese PLA General Hospital
Overall contact:
RiBao Wei, Master, Phone: +861055499133, Email: wrbbj2006@126.com
Summary
The purpose of this study is to compare the effect of valsartan and perindopril on HOMA-IR
Index in patients with chronic kidney disease.
Clinical Details
Official title: Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Homeostasis model of assessment for insulin resistence index (HOMA-IR index)
Secondary outcome: Glomerular filtration rate(eGFR) and Creatinine clearance rate(CCR)Body mass index(BMI) 24-h urine protein, urinary albumin-creatinin ration, retinol binding protein Cholesterol, triglycerides, high density lipoprotein, low density lipoprotein Glycosylated hemoglobin
Detailed description:
eligiable volunteers are administrated single-dose over the period I and II (crossover) of
Valsartan (80mg) as of Perindopril (4mg).
Every time before and after each medication, HOMA-IR index and other parameters and safety
of Valsartan (80mg) and Perindopril (4mg) is performed using a blood sample and conducting
some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical diagnosis of chronic kidney disease
- Serum creatinine: 1~3mg/dl
Exclusion Criteria:
- Diabetes
- Patients treated with corticosteroids or immunosuppressants
- BMI>30kg/m2
- SP>180mmHg, DP>110mmHg
- Patients with serious medical problems requiring specific medical treatment
Locations and Contacts
RiBao Wei, Master, Phone: +861055499133, Email: wrbbj2006@126.com
Chinese PLA General Hospital, Beijing, Beijing 100853, China
Additional Information
Related publications: Satirapoj B, Leelasiri K, Supasyndh O, Choovichian P. Short-term administration of an angiotensin II receptor blocker in patients with long-term hemodialysis patients improves insulin resistance. J Med Assoc Thai. 2014 Jun;97(6):574-81. Ushijima K, Takuma M, Ando H, Ishikawa-Kobayashi E, Nozawa M, Maekawa T, Shiga T, Fujimura A. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. Eur J Pharmacol. 2013 Jan 5;698(1-3):505-10. doi: 10.1016/j.ejphar.2012.11.022. Epub 2012 Nov 27. Iwashita M, Sakoda H, Kushiyama A, Fujishiro M, Ohno H, Nakatsu Y, Fukushima T, Kumamoto S, Tsuchiya Y, Kikuchi T, Kurihara H, Akazawa H, Komuro I, Kamata H, Nishimura F, Asano T. Valsartan, independently of AT1 receptor or PPARĪ³, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. Am J Physiol Endocrinol Metab. 2012 Feb 1;302(3):E286-96. doi: 10.1152/ajpendo.00324.2011. Epub 2011 Nov 1.
Starting date: November 2014
Last updated: November 29, 2014
|
